Therna Biosciences is Life Sciences Review’s Programmable RNA Therapeutics Company of the Year 2026. A profile on RNA-Logix™, our AI RNA Biologist, and why we design every RNA medicine for the biology of the disease it treats. www.lifesciencesreview.com/therna-biosc...

Chronos is out. Tens of thousands of synthetic mRNAs across ~50 human cell lines, tracked over time, in a single experiment. Penta-47x27K and Tria-47x28K, plus a technical white paper. Free to download. www.prnewswire.com/news-release...

Therna Biosciences is the Chiesi FAST Discovery Award winner and part of the Fall 2026 FAST California cohort at California Life Sciences. The award recognizes rare disease innovation and the platform technologies behind nucleotide therapeutics. www.califesciences.org/fast-califor...

New on the @thernabio.bsky.social blog: can a generator do the predictor's job alone? We showed a foundation model a few RNA sequences, all high-activity or all low-activity. No labels, no fine-tuning, just a prompt. Then asked for more. It came back matching what it was shown. Link below:

Individualized medicine is moving from concept to reality. New FDA guidance supports therapies designed for single patients with ultra rare diseases. At Therna Biosciences, we are building an AI enabled RNA platform to make this possible. Link to our CEO’s post in the comments

AI-enabled RNA design for ultra-rare diseases was on stage at PMWC and in a new Charles River feature last week. Two signs of a growing conversation around what is now possible. Link in comments. #RNA #PrecisionMedicine #RareDisease

Two urgent patients. One AI-driven approach. At PMWC, we are unveiling our collaboration with Charles River Labs to advance single-patient RNA medicines for ultra-rare conditions. Our AI platform designed better candidates, faster. #PrecisionMedicine #RareDisease #RNA

Therna Biosciences Appoints Biotech Veteran Devyn Smith, Ph.D., to Board of Directors and Expands Strategic and Scientific Advisory Leadership: Read the full news here: www.prnewswire.com/news-release...

Therna Biosciences has joined the NVIDIA Inception program, building on our work with NVIDIA and CodonFM to advance AI-driven RNA design and programmable RNA therapeutics. #NVIDIAInception #AI #RNA

Foundation models are essential for biology. Scaling is not failing but requires the right customization. They are indispensable in data-sparse domains and will drive the next decade of discovery. blog.therna.com/p/the-case-f...

The Case for Foundation Models in Biology

Rethinking scale: context, diversity, and design for biological foundation models

blog.therna.com

Excited to announce the launch of Therna Biosciences, The RNA company. By combining RNA biology with generative AI, we’re building programmable RNA medicines with greater durability, specificity and efficacy. Backed by $10M seed funding. www.webwire.com/ViewPressRel...

Therna Biosciences Launches with Proprietary Generative AI Models for Designing Programmable RNA Medicines

Therna Biosciences today announced its launch with a vision to transform the development of RNA medicines through a biology-guided, AI-powered platform. By decoding the language of RNA, Therna is pio...

webwire.com